NeoPharm CO. LTD (092730) — Capital Reinvestment Ratio
NeoPharm CO. LTD (092730) has a Capital Reinvestment Ratio of 0.08x as of September 2025, meaning it reinvests 0% of its operating cash flow (₩5.88 Billion) in capital expenditures (₩446.60 Million). Check NeoPharm CO. LTD tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
NeoPharm CO. LTD Capital Reinvestment Ratio (2012–2024)
This chart tracks NeoPharm CO. LTD's Capital Reinvestment Ratio across 11 annual periods. For the full cash flow conversion analysis, see NeoPharm CO. LTD (092730) cash conversion ratio.
Annual Capital Reinvestment Ratio for NeoPharm CO. LTD (2012–2024)
Year-by-year Capital Reinvestment Ratio for NeoPharm CO. LTD from 2012 to 2024. See NeoPharm CO. LTD free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.17x | ₩18.63 Billion | ₩3.08 Billion | ▼ -81.6% |
| 2023 | 0.90x | ₩23.26 Billion | ₩20.83 Billion | ▲ +1916.3% |
| 2022 | 0.04x | ₩18.16 Billion | ₩806.43 Million | ▲ +200.8% |
| 2021 | 0.01x | ₩21.68 Billion | ₩320.11 Million | ▼ -11.7% |
| 2020 | 0.02x | ₩17.07 Billion | ₩285.62 Million | ▼ -94.6% |
| 2019 | 0.31x | ₩19.22 Billion | ₩5.90 Billion | ▲ +155.9% |
| 2018 | 0.12x | ₩16.18 Billion | ₩1.94 Billion | ▲ +44.4% |
| 2017 | 0.08x | ₩10.65 Billion | ₩884.71 Million | ▼ -45.8% |
| 2016 | 0.15x | ₩9.16 Billion | ₩1.40 Billion | ▲ +18.8% |
| 2015 | 0.13x | ₩6.09 Billion | ₩786.89 Million | ▼ -57.8% |
| 2012 | 0.31x | ₩564.34 Million | ₩172.47 Million | — |